Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)

Trial Profile

Phase 1/2, Open Label & Double Blind Randomized Placebo-controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BGC-101-BioGenCell (Primary)
  • Indications Chronic limb-threatening ischemia; Peripheral arterial occlusive disorders
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms EnEPC-CLI
  • Sponsors BioGenCell

Most Recent Events

  • 06 Jun 2025 Planned number of patients changed from 50 to 40.
  • 19 Dec 2024 Status changed from recruiting to active, no longer recruiting, according to a BioGenCell media release.
  • 19 Dec 2024 According to a BioGenCell media release, phase 2 trial has completed patient recruitment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top